A first-in-class dual EZH2/HDAC inhibitor has been biologically investigated in AML cells, and its antileukemia activity is associated with proliferation inhibition, apoptosis induction and cell cycle arrest [60]. This evidence concerns the gene EZH2 and acute myeloid leukemia.